La Jolla Pharmaceutical Company (NASDAQ: LJPC) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock. And for technical investors there is some hope when looking at LJPC
After announcing that its phase 3 ATHOS-3 study would be published in a prestigious medical journal, clinical-stage biotech La Jolla Pharmaceutical (NASDAQ: LJPC) saw its shares ... David and Tom Gardner have a stock tip, it can …
Equities under review are: Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC), Cytori Therapeutics Inc. (NASDAQ: …
NBC 23mon
hey now! I love LJPC and all but it has been pretty slow latley. Check out the*stock-dork for some better plays. . In the short-term LJPC does not seem to be like a good trade. the other week Awe.Som.e.Sto-cks. alerted this company i …
stock is set for its best day since March 2014; current volume about 0.30 times their 25-day moving avg ** Co says drug, LJPC-501, induces statistically significant improvement in raising blood pressure, compared to a placebo ** Co says a …
La Jolla Pharmaceutical Co : La Jolla Pharmaceutical Company announces proposed underwritten public offering of common stock . La Jolla Pharmaceutical Co - announced its intention to offer and sell $100 million of its common stock
Reuters10mon
La Jolla Pharmaceutical Company (Pink Sheets: LJPC ... The termination follows La Jolla’s announcement on March 3, 2010, that its common stock would be suspended and delisted from The NASDAQ Stock Market (“Nasdaq”) effective …
LJPC-501, is La Jolla's formulation of a natural peptide that regulates blood pressure. It induced a statistically significant improvement in raising blood pressure, compared to a placebo, in the 344-patient study, the company said. La Jolla's …
Based on fundamentals, market trends, company events and news, and other factors, equity analysts assign price targets and recommendations to buy or sell a stock. The following graph shows how a survey of multiple analysts recommend …